Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Study ID
NCT01516567
Phase
PHASE2
Status
Completed

Conditions

  • Primary Mediastinal Large B Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
6 Months - 17 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Phase II trial to determine the efficacy of Dose Adjusted-EPOCH-Rituximab regimen in children and adolescent with primary mediastinal large B cell lymphoma in terms of event free survival.

Key Dates

Start date
Apr 1, 2012
Status verified
Feb 2026
Primary completion
Apr 30, 2017
Completion
Nov 16, 2022

Study Design

Enrollment
47 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: DA-EPOCH-R
    6 courses of Dose Adjusted-EPOCH-Rituximab

Primary Outcome Measure

Event free survival [ Time Frame: 36 months ]

Related Studies